Pulmonary Hypertension Trial, Recruiting (NCT06135909)

Pulmonary Hypertension Trial, Recruiting NCT06135909 Sponsor: Chinese Pulmonary Vascular Disease Research Group Condition: Pulmonary Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT06135909 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pulmonary Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are willing and able to sign a consent form agreeing to take part in the study
You are between 18 and 85 years old
You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) and are currently using, or planning to use, specific medications for this condition — these include drugs from any of the following groups: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists, or prostacyclin receptor agonists (confirm with trial site which medications count)

Who may not be able to join:

You have a history of mental illness or addiction to drugs or toxic substances that would prevent you from signing the consent form or fully participating in the study
You have been diagnosed with cancer or another serious illness where your life expectancy is less than 6 months
You have been taking pulmonary hypertension targeted medications for less than 2 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhihong Liu, M.D., Ph.D, Chinese Academy of Medical Sciences, Fuwai Hospital

Phone: 8601088396816

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06135909

Sponsor: Chinese Pulmonary Vascular Disease Research Group

Phase: Not Applicable

Status: Recruiting

Condition: Pulmonary Hypertension

Trial contact: 8601088396816

More information: https://clinicaltrials.gov/study/NCT06135909

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are willing and able to sign a consent form agreeing to take part in the study
You are between 18 and 85 years old
You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) and are currently using, or planning to use, specific medications for this condition — these include drugs from any of the following groups: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists, or prostacyclin receptor agonists (confirm with trial site which medications count)

Who may not be able to join:

You have a history of mental illness or addiction to drugs or toxic substances that would prevent you from signing the consent form or fully participating in the study
You have been diagnosed with cancer or another serious illness where your life expectancy is less than 6 months
You have been taking pulmonary hypertension targeted medications for less than 2 weeks

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese Pulmonary Vascular Disease Research Group

Registry

ClinicalTrials.gov

Start date

1 January 2020

Est. completion

31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of clinical worsening events 1 year after enrollment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov